Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase 2

Active, not recruiting

Conditions: Kidney Cancer

Interventions: Drug: Pazopanib
Drug: Bevacizumab
Drug: Everolimus

First Posted Date: 2010-10-08

Last Posted Date: 2025-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01217931

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2010-10-01

Last Posted Date: 2019-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT01213238

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoplasmacytic Lymphoma

Interventions: Biological: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-09-27

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT01209871

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Phase 2

Completed

Conditions: Ampulla of Vater Adenocarcinoma
Stage IIIA Ampulla of Vater Cancer AJCC v8
Stage IIIB Ampulla of Vater Cancer AJCC v8
Stage IIIB Small Intestinal Adenocarcinoma AJCC v8
Stage IV Small Intestinal Adenocarcinoma AJCC v8
Stage III Ampulla of Vater Cancer AJCC v8
Stage III Small Intestinal Adenocarcinoma AJCC v8
Stage IV Ampulla of Vater Cancer AJCC v8
Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Small Intestinal Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2010-09-23

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01208103

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Procedure: Ductal Lavage Fluid Collection

First Posted Date: 2010-09-23

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT01207635

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer

Early Phase 1

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Metformin

First Posted Date: 2010-09-20

Last Posted Date: 2017-06-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01205672

Locations: 🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Procedure: Prophylactic White Cell Transfusion
Procedure: Therapeutic White Cell Transfusion

First Posted Date: 2010-09-17

Last Posted Date: 2015-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT01204788

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PKC412 and 5-Azacytidine

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: 5-azacytidine
Drug: PKC412

First Posted Date: 2010-09-16

Last Posted Date: 2018-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT01202877

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Relaxation for Women With Breast Cancer Undergoing Radiotherapy

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaires
Other: Relaxation Program
Other: Saliva Testing

First Posted Date: 2010-09-16

Last Posted Date: 2025-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 681

Registration Number: NCT01202851

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Phase 2

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Panitumumab

First Posted Date: 2010-09-15

Last Posted Date: 2020-02-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01202409

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy